[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.119.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
The World in Medicine
December 9, 1998

Fighting Lymphatic Filariasis

Author Affiliations
 

Not Available

Not Available

JAMA. 1998;280(22):1898. doi:10.1001/jama.280.22.1898-JWM80009-2-1

The World Health Organization (WHO) has come one step closer to its goal of eliminating lymphatic filariasis by 2020 with a pharmaceutical manufacturer's expansion of its drug donation program in Africa.

Officials at Merck & Co Inc announced recently that the company will donate ivermectin for the treatment of lymphatic filariasis. Merck has donated the drug for more than 10 years for the treatment of onchocerciasis, or river blindness, in Africa. Merck officials decided to expand the program after they received French regulatory approval earlier this year for the use of ivermectin to treat lymphatic filariasis, a parasitic disease transmitted by mosquitoes.

First Page Preview View Large
First page PDF preview
First page PDF preview
×